Azilect® – a well tolerated therapy

Azilect® (rasagiline) – a well tolerated therapy for early and moderate-to-advanced Parkinson's disease patients.

Parkinson’s disease animations

View the animations to learn more about Parkinson's disease. They can be helpful in communicating with your patients.

Azilect® – treating the symptoms of Parkinson's disease

Want to know more about Azilect®?

Azilect® (rasagiline) has demonstrated efficacy in 4 large clinical trials, both as monotherapy (TEMPO, ADAGIO) and as an adjunct to levodopa in Parkinson's disease patients (PRESTO, LARGO).

ADAGIO trial results show Azilect® slows clinical progression of Parkinson’s disease

The ADAGIO study showed that Parkinson's disease patients who took Azilect® (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement...